GlassScriptPhysician profile
Sarah S Puckett
NPI 1831199421
$2,234.34
in general payments reported to CMS, 2019-2025
31 companies · $401 in 2025
The $401 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $223 · 2021: $74.44 · 2022: $199 · 2023: $364 · 2024: $475 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $245.84 | 2019 | |
| Sumitomo Pharma America, INC. | $213.01 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $201.12 | 2019-2025 | Paragard T 380a |
| Astellas Pharma US INC | $183.81 | 2023-2025 | Veozah |
| Sage Therapeutics, LLC | $138.69 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $135.53 | 2022-2025 | Slynd |
| Abbvie INC. | $125.42 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $113.83 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.00 | 2019-2025 | |
| Pfizer INC. | $96.71 | 2019-2024 | |
| Amgen INC. | $88.15 | 2019-2023 | Evenity, Prolia |
| Daiichi Sankyo INC. | $76.26 | 2021-2024 | Injectafer |
| Exact Sciences Corporation | $74.12 | 2023-2025 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $56.98 | 2019-2022 | |
| Hologic Sales and Service, LLC | $49.35 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $40.51 | 2019 | |
| Agile Therapeutics, INC. | $40.05 | 2022 | |
| Novo Nordisk INC | $28.78 | 2021-2022 | |
| Duchesnay USA Incorporated | $25.16 | 2019 | |
| Allergan, INC. | $19.89 | 2019 | |
| Minerva Surgical, INC | $19.41 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $18.27 | 2022 | |
| Shield Therapeutics INC | $17.50 | 2023 | Accrufer |
| Amarin Pharma, INC. | $16.72 | 2021 | |
| Conmed Corporation | $16.45 | 2021 | |
| Organon LLC | $16.45 | 2024 | |
| Dysis Medical, INC. | $16.09 | 2020 | |
| Merck Sharp & Dohme LLC | $12.79 | 2019 | |
| Lupin INC. | $12.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.57 | 2021 | |
| Mylan Pharmaceuticals INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Puckett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.